Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations(17 sites)
China
Peking University Sixth Hospital, Beijing, Beijing Municipality Peking Union Medical College Hospital, Beijing, Beijing Municipality Liangxiang Hospital, Beijing, Beijing Municipality Guiyang Second People's Hospital, Guiyang, Guizhou Baoding Seventh Hospital, Baoding, Hebei Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Dengzhou People's Hospital, Dengzhou, Henan Second People Hospital of Nanyang, Nanyang, Henan The Second People's Hospital of Huai'an, Huaian, Jiangsu Nantong First People's Hospital, Nantong, Jiangsu Suqian People's Hospital, Suqian, Jiangsu Wuxi Third People's Hospital, Wuxi, Jiangsu Qinghai University Affiliated Hospital, Xining, Qinghai West China Longquan Hospital Sichuan University, Chengdu, Sichuan The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang Jinhua Municipal Central Hospital, Jinhua, Zhejiang Lishui Municipal Central Hospital, Lishui, Zhejiang